RLAY - Relay Therapeutics inks a worldwide license and collaboration agreement with Genentech for RLY-1971

Relay Therapeutics (RLAY) has signed a worldwide license and collaboration agreement with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, a potent inhibitor of SHP2 to expand into multiple combination studies including with Genentech’s investigational inhibitor of KRAS G12C, GDC-6036. “RLY-1971 has the potential to serve as a backbone for combination therapy across numerous solid tumors and therefore represents an encouraging approach for cancer patients,” said Sanjiv Patel, M.D., president and chief executive officer of Relay Therapeutics. “Roche and Genentech’s global footprint and deep expertise in oncology makes them the perfect partner for us to execute the broad development and commercialization of RLY-1971.” The company will receive $75M upfront and is eligible to receive an additional $25M in near-term payments and $695M in additional potential milestones, plus royalties on global net product sales. Relay Therapeutics anticipates to have enough cash and investments to sustain its operations

For further details see:

Relay Therapeutics inks a worldwide license and collaboration agreement with Genentech for RLY-1971